依帕司他联合己酮可可碱在糖尿病足治疗中的临床效果与安全性研究  

Study on the Clinical Effect and Safety of Epalrestat Combined with Pent⁃oxifylline in the Treatment of Diabetic Foot

作　　者：连重鞅 范力 LIAN Zhongyang;FAN Li(Department of Vascular Diseases,Lanzhou Traditional Chinese Medicine Hospital,Lanzhou 730050,Gansu,China)

机构地区：[1]兰州市中医医院脉管病科,甘肃兰州730050

出　　处：《糖尿病新世界》2024年第15期1-4,8,共5页Diabetes New World

基　　金：兰州市卫生健康科技发展项目项目资助(A2023018)。

摘　　要：目的分析依帕司他联合己酮可可碱在糖尿病足治疗中的临床效果与安全性。方法选取2022年2月—2024年3月兰州市中医医院收治的68例糖尿病足患者为研究对象,按照不同的用药方法分为两组,各34例。对照组采用依帕司他治疗,观察组采用依帕司他联合己酮可可碱治疗,比较两组治疗效果、足背动脉血供指标、炎症因子水平、不良反应发生率、生活质量。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组足背动脉血管内径、搏动指数、血流流速均高于对照组,阻力指数低于对照组,差异有统计学意义(P均<0.05)。观察组C反应蛋白、白细胞介素-6、肿瘤坏死因子-α水平均低于对照组,差异有统计学意义(P均<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。观察组社会功能、躯体质量、角色功能、情绪功能评分均高于对照组,差异有统计学意义(P均<0.05)。结论对糖尿病足患者采取依帕司他联合己酮可可碱治疗,治疗效果良好,用药安全性高,且可提高患者生活质量,临床应用价值显著。Objective To analyze the clinical effect and safety of epalrestat combined with pentoxifylline in the treat⁃ment of diabetic foot.Methods A total of 68 patients with diabetic foot admitted to Lanzhou Traditional Chinese Medi⁃cine Hospital from March 2021 to March 2024 were selected as the research objects.They were divided into two groups according to different medication methods,with 34 cases in each group.The control group was treated with ep⁃alrestat,and the observation group was treated with epalrestat combined with pentoxifylline.The therapeutic effect,dorsal artery blood supply index,inflammatory factor level,incidence of adverse reactions and quality of life were com⁃pared between the two groups.Results The total effective rate of the observation group was higher than that of the con⁃trol group,and the difference was statistically significant(P<0.05).The inner diameter,pulsatility index and blood flow velocity of dorsalis pedis artery in the observation group were higher than those in the control group,the resis⁃tance index was lower than that in the control group,and the differences were statistically significant(all P<0.05).The levels of C-reactive protein,interleukin-6 and tumor necrosis factor-αin the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The incidence of adverse re⁃actions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).The scores of social function,physical quality,role function and emotional function in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion Patients with diabetic foot were treated with epalrestat combined with pentoxifylline has a good therapeu⁃tic effect,high safety,and can improve the quality of life of patients,the clinical application value is significant.

关 键 词：依帕司他 己酮可可碱 糖尿病足 临床效果 安全性 

分 类 号：R587[医药卫生—内分泌]